Change the DNA of Your Portfolio:
Growth Opportunities Through Genomics

Thanks to DNA sequencing and the genomic revolution, we could be on the cusp of a brand-new era of healthcare solutions that could extend and enhance the quality of human life. Several key biotech companies are pioneering scientific developments that can change everything we know about healthcare.
In this upcoming webcast, join ARK Invest and VettaFi for a deep-dive discussion on the companies driving change in targeted therapeutics, bioinformatics, CRISPR technology, and more.

June 8, 2022
11am PT | 2pm ET
Already Registered? Click here »


Topics will include:

  • Predictions for growth in biotech for the rest of 2022—and beyond.
  • A close look at relevant biotech companies in the space, including Teladoc and Exact Sciences.
  • How financial advisors can incorporate a biotech sleeve to enhance an investment portfolio.

NOT accepted for one hour of CFP/CIMA CE credit for live and on-demand attendees

CFA Institute members are encouraged to self-document their continuing professional development activities in their online CE tracker.


Nicholas Grous

Associate Portfolio Manager
ARK Invest

Simon Barnett

Research Analyst
ARK Invest

Todd Rosenbluth

Head of Research

By registering, you are certifying that you are a financial professional and agree to share your data with VettaFi and opt-in to receiving occasional communications about projects and events. The contents of this form are subject to VettaFi's Privacy Policy. You can unsubscribe at any time.

Important Disclosures

Investing involves risks and principal loss is possible. Companies that the Adviser believes are capitalizing on disruptive innovation and developing technologies to displace older technologies or create new markets may not in fact do so. Companies that initially develop a novel technology may not be able to capitalize on the technology. Companies that develop disruptive technologies may face political or legal attacks from competitors, industry groups or local and national governments. These companies may also be exposed to risks applicable to sectors other than the disruptive innovation theme for which they are chosen, and the securities issued by these companies may underperform the securities of other companies that are primarily focused on a particular theme.

Investors should carefully consider the investment objectives and risks as well as charges and expenses of an ARK ETF before investing. Investing involves risk including possible loss of principal. This and other information are contained in the ARK ETFs’ prospectuses and SAI, which may be obtained by going to www.ark-funds.com. The prospectus and SAI should be read carefully before investing. 

Distributor: Foreside Fund Services, LLC